CURE HIV, INC. AND GLOBAL HUMANCEUTICALS, INC. SEEK INTERNATIONAL PATENT ON DRUG TO COMBAT HIV/AIDS
Cure HIV, Inc. and Global Humanceuticals, Inc. Seek International Patent on Drug to Combat HIV/AIDS
HILTON HEAD, S.C., Aug. 8 /PRNewswire/ - Dr. Roger Kenneth Hershline M.D.,
Ph.D., founder of Cure HIV, Inc. and Global Humanceuticals, Inc., announced
today that he has applied for an international patent on his antiviral
composition. He has received International Publication No. WO2006/050381
published on May 6, 2006. Dr. Hershline was issued a United States Patent
#6,821,958 on November 23, 2004 for this new low-cost, highly effective,
nontoxic medication for the prevention and treatment of HIV/AIDS. The
international patent will allow him to proceed with clinical studies and is the
next step in getting this topical microbicide to market.
Pre-clinical studies of this antiviral composition have been conducted by
leading scientists at the National Institutes of Health. The NIH has encouraged
Dr. Hershline to proceed with clinical studies.
Approximately 7,000 women, mostly young women of child-bearing age, become
infected with the HIV virus every day. The creation of an effective and
affordable microbicide would enable women to protect themselves against the HIV
virus transmitted through sexual intercourse, the leading form of transmission
worldwide.
Global Humanceuticals’ goal is to produce this microbicide with Dr. Hershline’s
antiviral composition. It will require tens of millions of dollars to complete
the pre-clinical and clinical trials of this new microbicide. Cure HIV’s goal is
to raise the funds necessary to accomplish this task.
Cure HIV needs financial support to complete pre-clinical and clinical
development of this new medication.
CURE HIV, INC. established to produce affordable HIV preventative
Dr. Roger Hershline has patent on new low-cost, food-based, non-toxic medication for prevention and treatment of HIV/AIDS
Hilton Head, SC, June 7, 2006―Dr. Roger Kenneth Hershline announces today that he has established CURE HIV, a not-for-profit public charity, to raise money to proceed with the development of this new medication as a topical microbicide with the intent of preventing HIV/AIDS transmission through intercourse, which is the leading cause of HIV/AIDS today.
Dr. Hershline was issued a United States Patent #6,821,958 on November 23, 2004 for a new low-cost, food-based, nontoxic medication for the prevention and treatment of HIV/AIDS.
Pre-clinical studies of this medication have been conducted by leading scientists at the National Institutes of Health and have demonstrated high activity against the HIV/AIDS virus. The National Institutes of Health has encouraged Dr. Hershline to proceed with clinical studies.
"As a physician, I cannot stand by and wait while this disease spreads and people are dying" said Dr. Hershline. "I have started CURE HIV to support the development and testing of this new medication. We are going to put this medication in the hands of the people who need it although we realize that it will require tens of millions of dollars to accomplish this."
CURE HIV needs financial support to complete pre-clinical and clinical development of this new medication.
About CURE HIV, INC
CURE HIV, INC. is a not-for-profit organization dedicated to the production of an affordable preventative for HIV and to the continuation of research and development of a cure for HIV/AIDS and other viruses CURE HIV, INC. was established by Dr. Roger K. Hershline in the hopes that his philanthropic donation of the medication to South Africa would motivate people, organizations and foundations to donate funds to help complete pre-clinical and clinical trials of this effective medication.
Contact Information:
CURE HIV, INC.
P. O. Box 23467
Hilton Head Island, SC 29925
info@curehiv.us
Medical information: Cure HIV, Inc. does not intend to provide specific medical advice or treatment. Cure HIV, Inc. intends to provide the website visitors with documents and information to better understand HIV / AIDS and its prevention and treatment.